Get In Touch
Xeraya Capital Sdn Bhd
26.03–26.08, G Tower
#199 Jalan Tun Razak, KL
+603 2381 8700
Submit a Proposal

Acutus Medical Expands AFib Offerings; Announces Strategic Acquisition and New Partnerships in Monitoring and Therapy

SAN FRANCISCO, May 9, 2019 /PRNewswire/ — Today at the 40th annual Heart Rhythm Scientific Sessions, Acutus Medical announced the agreement to acquire Rhythm Xience, Inc., and new strategic partnerships with Peerbridge Health, Cardiac Designs and MedFact. Acutus’ expanded portfolio builds on the organization’s unprecedented mapping and visualization technology platform. Acutus is committed to helping electrophysiologists improve patient outcomes and reduce AFib burden by delivering world-class cardiac access, novel arrhythmia diagnostics, innovative therapies and wireless multi-channel monitoring.

“At Acutus, we are challenging the status quo by building a suite of next generation products on an open platform that improves EP lab efficiency and effectiveness,” said Acutus Medical CEO Vince Burgess. “Our dynamic business model addresses the entire patient care continuum and is elevating electrophysiology. We are positioned to become the only focused arrhythmia care company with a complete suite of solutions that electrophysiologists need to diagnose, treat and follow patients with atrial arrhythmias.”

The Rhythm Xience acquisition and partnership agreements create a foundation for Acutus to provide solutions spanning access, therapy, diagnostics and rhythm monitoring:

Access Sheaths and Introducers
Acutus is acquiring Rhythm Xience, known for its integrated family of highly novel and user-friendly transseptal crossing and steerable introducer systems. This acquisition expands Acutus’ ability to improve access and effectively treat arrhythmias with: Flextra, a two-way steerable introducer sheath; Guider, a fixed curve introducer and Lancer, a transseptal crossing device. All products are FDA cleared and commercially available.

To ensure early detection as well as to validate treatment efficacy, Acutus has partnered with Peerbridge Health to offer the most advanced ambulatory ECG, The Peerbridge Cor™. The Peerbridge system offers the only truly wireless multi-channel ECG monitor that is FDA cleared to detect up to 26 different arrhythmias. The system records every heartbeat for up to seven days and can transmit patient activated events via the cloud, ensuring accelerated arrhythmia detection by clinical staff. At the end of each test, a quantitative analysis and AFib burden summary is delivered to prescribing physicians summarizing every cardiac event, both asymptomatic and patient activated.

For longer term remote monitoring, the Acutus QCheck handheld ECG and mobile app are now available through a partnership with Cardiac Designs. When individuals experience arrhythmia symptoms, QCheck records heart data and quickly displays results in the mobile app, which can then be transmitted to a medical professional via email or text. QCheck is available in the Apple App Store and Google Play by prescription or over the counter. All monitoring products are FDA cleared and commercially available.

Robotic Ablation Catheters to Deliver Therapy Solutions
Acutus has signed an exclusive agreement with MedFact to distribute its robotically enabled point RF ablation catheter utilized for the Stereotaxis robotic navigation system. This agreement further enhances Acutus’ integration with the Stereotaxis navigation system announced earlier this year.

The Acutus portfolio also includes its leading AcQMap advanced cardiac imaging and mapping system. AcQMap is the first and only cardiac mapping system that incorporates precision ultrasound atrial anatomy reconstruction and highly reproducible, high-definition non-contact charge density mapping. The system also provides workhorse contact mapping capabilities, now available in Europe. AcQMap’s increased clarity of arrhythmia pattern mapping aids in the development of patient specific ablation strategies. Unique to this system, physicians can rapidly remap and confirm the efficacy of each ablation.